Australia markets open in 4 hours 34 minutes

InnoCare Pharma Limited (INCPF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
3.26000.0000 (0.00%)
As of 09:40AM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 1.30B
Enterprise value 349.47M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)253.92
Price/book (mrq)5.74
Enterprise value/revenue 0.93
Enterprise value/EBITDA -5.47

Trading information

Stock price history

Beta (5Y monthly) 1.12
52-week change 30.00%
S&P500 52-week change 326.27%
52-week high 33.2600
52-week low 33.2600
50-day moving average 33.2600
200-day moving average 33.2600

Share statistics

Avg vol (3-month) 3N/A
Avg vol (10-day) 3N/A
Shares outstanding 51.5B
Implied shares outstanding 61.5B
Float 8934.46M
% held by insiders 130.49%
% held by institutions 136.02%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in CNY.

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin -85.47%
Operating margin (ttm)-95.93%

Management effectiveness

Return on assets (ttm)-4.37%
Return on equity (ttm)-8.71%

Income statement

Revenue (ttm)738.54M
Revenue per share (ttm)0.43
Quarterly revenue growth (yoy)9.50%
Gross profit (ttm)N/A
EBITDA -650.15M
Net income avi to common (ttm)-631.26M
Diluted EPS (ttm)-0.0300
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)8.29B
Total cash per share (mrq)4.7
Total debt (mrq)1.65B
Total debt/equity (mrq)23.05%
Current ratio (mrq)4.21
Book value per share (mrq)4.05

Cash flow statement

Operating cash flow (ttm)-665.49M
Levered free cash flow (ttm)-837.22M